[Perspectives in the use of monoclonal antibodies in the therapy of neoplastic diseases].
In order to improve the efficiency of monoclonal antibodies against tumor-associated antigens, conjugates with toxins, cytostatics or radionuclides have been tested. Furthermore, antibody genes or gene segments can be altered or exchanged to reach enhanced specificity or novel biological functions of immunoglobulin molecules. In addition, monoclonal antibodies have been used recently for the direction, stimulation and activation of T lymphocytes, which are able to generate cytolytic potential against tumor cells. In this study we demonstrate selective activation and expansion of T-cell subpopulations by cross-linking the T-cell receptor complex with other differentiation antigens.
Emmrich
F
F
D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D006801:Humans; D008213:Lymphocyte Activation; D009369:Neoplasms / Q000532:radiotherapy / Q000628:therapy*; D011868:Radioisotopes / Q000627:therapeutic use; D013601:T-Lymphocytes / Q000276:immunology
D000911:Antibodies, Monoclonal; D011868:Radioisotopes
Perspektiven der Anwendung monoklonaler Antikörper in der Therapie neoplastischer Erkrankungen.